## Correct Answer: D. Chemoradiation This patient presents with **locally advanced cervical cancer (LACC)** — the clinical hallmark is a necrotizing growth with **parametrial involvement**, which defines FIGO stage IIB or higher. The foul-smelling bloody discharge and mucous are typical of an ulcerating cervical malignancy. Parametrial involvement is the critical discriminator: it indicates the tumor has breached the cervical stroma and invaded the parametrium, making it unresectable by simple hysterectomy alone. For LACC (FIGO stage IB2–IVA), the **gold standard of care is concurrent chemoradiation (CCRT)**, as established by landmark trials (RTOG 90-01, GOG 165) and endorsed by Indian guidelines (NCCN, ICMR). The rationale is twofold: (1) **external beam radiotherapy (EBRT)** targets the primary tumor and pelvic lymph nodes, and (2) **concurrent chemotherapy** (typically cisplatin 40 mg/m² weekly) acts as a radiosensitizer, improving local control and overall survival by ~10–15% compared to radiation alone. Brachytherapy is added after EBRT completion to boost the primary tumor dose. Parametrial involvement precludes primary surgery because: (a) margins cannot be achieved without sacrificing vital structures (ureter, bladder, rectum), and (b) residual disease risk is prohibitively high. Thus, CCRT is the definitive curative approach in this setting, with 5-year survival rates of 60–70% in appropriately selected patients. ## Why the other options are wrong **A. Chemotherapy** — Chemotherapy alone is **palliative**, not curative, for LACC. It is reserved for metastatic or recurrent disease. In locally advanced disease, chemotherapy must be **concurrent with radiation** to act as a radiosensitizer and achieve locoregional control. Standalone chemotherapy lacks the dose intensity and local effect needed to control a bulky parametrial tumor. **B. Brachytherapy** — Brachytherapy alone is **insufficient** for LACC with parametrial involvement. Brachytherapy delivers high-dose radiation to the cervix and paracervical tissues but cannot adequately cover the pelvic sidewall and parametrium. It is used as a **boost after EBRT completion**, not as monotherapy. EBRT is mandatory first to treat the parametrium and pelvic nodes. **C. Surgery** — Primary surgery (radical hysterectomy with pelvic lymphadenectomy) is **contraindicated** in LACC with parametrial involvement because: (1) margins cannot be achieved without sacrificing bladder/rectum/ureter, (2) residual disease risk is unacceptably high, and (3) morbidity is severe. Surgery may be considered only for early-stage disease (IA–IB1) or as salvage for recurrent disease after CCRT. ## High-Yield Facts - **FIGO stage IIB or higher** (parametrial involvement) = LACC → **concurrent chemoradiation is DOC**, not surgery or RT alone. - **Cisplatin 40 mg/m² weekly** during EBRT improves 5-year OS by ~10–15% vs. RT alone (landmark RTOG 90-01 trial). - **EBRT (45–50 Gy) + concurrent chemotherapy + brachytherapy boost (20–30 Gy)** = standard CCRT regimen for LACC. - **Parametrial involvement** = tumor has crossed cervical stroma into parametrium → unresectable, mandates radiation-based approach. - **Brachytherapy is never monotherapy** for LACC; it is always a boost after EBRT to increase local dose to primary tumor. ## Mnemonics **LACC Management: EBRT-CHEMO-BRACHY** **E**BRT (external beam) + **CHEMO** (concurrent cisplatin) + **BRACHY** (brachytherapy boost). This is the sequence and the mantra for locally advanced cervical cancer. Use when you see parametrial involvement or FIGO ≥IIB. **Parametrium = Radiation, Not Surgery** If the tumor touches the **parametrium**, think **radiation**. Parametrial involvement = unresectable → CCRT is the only curative option. Surgery is off the table. ## NBE Trap NBE may lure students with parametrial involvement to choose **surgery** (confusing it with early-stage disease where radical hysterectomy is appropriate) or **brachytherapy alone** (forgetting that EBRT is mandatory for pelvic sidewall coverage). The trap is not recognizing that **parametrial involvement = LACC = radiation-based**, not surgery-based. ## Clinical Pearl In Indian tertiary centers, CCRT for LACC is increasingly accessible via government cancer institutes (AIIMS, TATA Memorial). A 50-year-old woman with parametrial involvement has a realistic 5-year cure rate of 60–70% with CCRT, whereas surgery alone would leave her with uncontrolled pelvic disease and severe morbidity. This is why parametrial involvement is the **clinical red flag** that shifts management from surgery to chemoradiation. _Reference: DC Dutta's Textbook of Gynaecology (6th ed.), Ch. 19 (Cervical Cancer); Harrison's Principles of Internal Medicine, Ch. 87 (Gynecologic Malignancies); NCCN Clinical Practice Guidelines for Cervical Cancer (2023)._
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.